Search Results

242 Results for "korro bio.rss".

Sort By

RNA editing

Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal

Korro Bio is moving back to square one as a preclinical biotech after the failure of KRRO-110 in alpha-1 antitrypsin deficiency. The company’s stock is down 80% on all the news.

November 13, 2025
·
3 min read
·
Annalee Armstrong
Press Releases

Korro to Host Virtual Analyst Day on January 27, 2026

January 20, 2026
·
8 min read
RNA editing

JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position

After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop partnerships, pitch the potential of its new AATD program and find more money to keep the dream alive.

January 16, 2026
·
3 min read
·
Dan Samorodnitsky
Press Releases

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 8, 2026
·
1 min read
Press Releases

Korro to Participate in Upcoming Investor and Scientific Conferences

September 3, 2025
·
2 min read
Press Releases

Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs

November 13, 2025
·
15 min read
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer

After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 antitrypsin deficiency landscape is coming into focus, with Wave and Beam Therapeutics leading the way.

February 2, 2026
·
3 min read
·
Heather McKenzie
Press Releases

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 12, 2025
·
12 min read
Press Releases

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

July 22, 2025
·
7 min read
Press Releases

Korro to Participate in Upcoming Investor Conferences - May 14, 2025

May 15, 2025
·
2 min read